Ironwood Pharmaceuticals, Inc. (IRWD) CFO Gina Consylman Sells 864 Shares
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Gina Consylman sold 864 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $15.20, for a total value of $13,132.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Gina Consylman also recently made the following trade(s):
- On Friday, August 18th, Gina Consylman sold 207 shares of Ironwood Pharmaceuticals stock. The stock was sold at an average price of $14.34, for a total value of $2,968.38.
Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded down $0.27 during mid-day trading on Tuesday, hitting $14.98. The company’s stock had a trading volume of 1,300,400 shares, compared to its average volume of 1,305,889. Ironwood Pharmaceuticals, Inc. has a one year low of $13.43 and a one year high of $19.94. The company has a current ratio of 4.87, a quick ratio of 4.86 and a debt-to-equity ratio of -22.31.
COPYRIGHT VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/14/ironwood-pharmaceuticals-inc-irwd-cfo-gina-consylman-sells-864-shares.html.
Several equities research analysts have recently weighed in on IRWD shares. BidaskClub raised Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 17th. Wells Fargo & Company set a $19.00 price target on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, July 22nd. Wood & Company downgraded Ironwood Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Friday, July 21st. Finally, ValuEngine upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $18.29.
Several institutional investors have recently bought and sold shares of IRWD. Janus Henderson Group PLC purchased a new stake in shares of Ironwood Pharmaceuticals in the second quarter valued at approximately $150,460,000. EcoR1 Capital LLC raised its holdings in Ironwood Pharmaceuticals by 29.2% during the second quarter. EcoR1 Capital LLC now owns 3,753,635 shares of the biotechnology company’s stock worth $70,869,000 after purchasing an additional 848,120 shares during the last quarter. Pictet Asset Management Ltd. raised its holdings in Ironwood Pharmaceuticals by 37.5% during the third quarter. Pictet Asset Management Ltd. now owns 2,622,507 shares of the biotechnology company’s stock worth $41,357,000 after purchasing an additional 715,147 shares during the last quarter. Penn Capital Management Co. Inc. raised its holdings in Ironwood Pharmaceuticals by 258.4% during the second quarter. Penn Capital Management Co. Inc. now owns 855,314 shares of the biotechnology company’s stock worth $16,261,000 after purchasing an additional 616,686 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Ironwood Pharmaceuticals by 5.7% during the first quarter. Vanguard Group Inc. now owns 10,505,461 shares of the biotechnology company’s stock worth $179,223,000 after purchasing an additional 562,179 shares during the last quarter. Hedge funds and other institutional investors own 98.83% of the company’s stock.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.